| Literature DB >> 35433270 |
Rosara M Bass1,2, Babette S Zemel1,2, Virginia A Stallings1,2, Mary B Leonard3, Jaime Tsao4, Andrea Kelly2,4.
Abstract
Background: Pediatric bone accrual governs peak bone mass and strength. Longitudinal studies of bone health in youth with cystic fibrosis (CF) may provide insight into CF-related bone disease (CFBD), a prevalent co-morbidity in adults with CF.Entities:
Keywords: BMC, Bone mineral content; Bone accrual; Bone health; CF, Cystic Fibrosis; Cystic fibrosis; DXA velocity; DXA, Dual energy x-ray densiometry; FEV1, Forced expiratory volume in one second; HAZ, height-for-age-z-score adjustd; HV, height velocity; LBM, lean body mass; LS, lumbar spine; Peripheral quantitative computed tomography; TBLH, total body less head; Vel-Z, velocity-Z; Z-score; aBMD, areal bone mineral density; pQCT, peripheral quantitative tomography
Year: 2022 PMID: 35433270 PMCID: PMC9006323 DOI: 10.1016/j.jcte.2022.100297
Source DB: PubMed Journal: J Clin Transl Endocrinol ISSN: 2214-6237
Baseline data for reference and CF groups by sex.
| Males | P-Value | ||
|---|---|---|---|
| Reference (N = 68) | CF (N = 36) | ||
| Age (y) | 11.2 [5.1; 17.9] | 10.8 [5.9; 17.8] | 0.54 |
| Height-Z | 0.20 [−1.86; 2.13] | −0.35 [−2.01; 0.95] | 0.002 |
| Weight-Z | 0.34 [−1.52; 2.39] | −0.34 [−1.32; 1.11] | 0.004 |
| BMI-Z | 0.14 [−1.62; 2.10] | −0.05 [−1.39; 1.18] | 0.23 |
| Pubertal Stage: 1, 2, 3, 4, 5 | 30 (44%), 9 (13%), 7 (10%), 12 (17%), 9 (13%) | 17 (47%), 11 (30%), 5 (14%), 2 (6%), 1 (3%) | 0.06 |
| FEV1%-predicted | – | 100 [48; 136] (n = 34) | – |
| Age (y) | 12.1 [5.3; 17.1] | 9.3 [5.5; 16.4] | 0.07 |
| Height-Z | 0.37 [−1.24; 1.95] | −0.77 [−2.63; 1.72] | <0.0001 |
| Weight-Z | 0.34 [−1.27; 1.91] | −0.42 [−1.94; 1.36] | <0.0001 |
| BMI-Z | 0.20 [−1.44; 2.02] | −0.25 [−1.48; 1.61] | 0.047 |
| Pubertal Stage: 1, 2, 3, 4, 5 | 24 (32%), 8 (10%), 12 (16%), 27 (36%), 5 (6%) | 12 (46%), 6 (23%), 3 (12%), 5 (19%), 0 | 0.14 |
| FEV1%-predicted | – | 93.5 [36; 161] | – |
Fig. 1HV-only adjusted vs LBMV and HV adjusted Bone Accrual in CF. HV-LSaBMD-Vel-Z did not differ from LBMV-HV-LSaBMD-Vel-Z in either males (p = 0.27) or females (p = 0.45) with CF; line of identity . Similarly, HV-TBLH-BMC-Vel-Z did not differ from LBMV-HV-TBLH-BMC-Vel-Z in either males (p = 0.54) or females (p = 0.43) with CF.
Fig. 2Relationships between HV-LSaBMD-Vel-Z and clinical parameters in CF. In males with CF, HV-LSaBMD-Vel-Z and LBMV-HV-LSaBMD-Vel-Z (rho: −0.47; p = 0.0046) were negatively correlated with age. HV-LSaBMD-Vel-Z was positively correlated with BMI-Z; the latter relationship did not persist for LBMV-HV-LSaBMD-Vel-Z (rho: 0.14; p = 0.42). In females with CF, neither HV-LSaBMD-Vel-Z nor LBMV-HV-LSaBMD-Vel-Z were related to age while the tendency for higher HV-LSaBMD-Vel-Z with increasing BMI-Z did not persist for LBMV-HV-LSaBMD-Vel-Z (rho: 0.15; p = 0.49). Lines of fit are shown in blue. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 3Relationships of Section Modulus-Z with clinical parameters in CF and reference groups. Section Modulus-Z, a marker of bone strength, was correlated with BMI-Z but not age in both CF and reference males and was also correlated with FEV1 in males with CF. In females, Section Modulus-Z was negatively correlated with age in CF but not in the reference group. As with males, Section Modulus-Z was correlated with BMI-Z in both CF and reference females and was also correlated with FEV1 in CF. Lines of fit are shown in black for reference and in blue for CF. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Longitudinal model of pQCT-Z outcomes over one year in CF vs Reference adjusted for sex and baseline age and BMI-Z.
| pQCT-Z Score | Baseline Age | BMI-Z | Visit | CF Group | CF Group*Visit | CF Group*Sex | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Section Modulus | −0.01 | 0.20 | 0.51 | <0.001 | −0.08 | 0.41 | −0.56 | <0.001 | 0.14 | 0.41 | 0.27 | 0.11 |
| Cortical Density | −0.05 | 0.003 | 0.02 | 0.770 | 0.02 | 0.87 | −0.30 | 0.13 | −0.20 | 0.39 | 0.50 | 0.04 |
| Cortical Area | 0.00 | 0.73 | 0.55 | <0.001 | −0.06 | 0.52 | −0.64 | <0.001 | 0.20 | 0.28 | 0.45 | 0.01 |
| Cortical Thickness | 0.005 | 0.72 | 0.41 | <0.001 | −0.03 | 0.81 | −0.62 | 0.0010 | 0.24 | 0.26 | 0.68 | 0.001 |
| Periosteal Circumference | −0.01 | 0.32 | 0.49 | <0.001 | −0.07 | 0.42 | −0.39 | 0.003 | 0.11 | 0.50 | 0.08 | 0.61 |
| Endosteal Circumference | −0.01 | 0.35 | 0.20 | <0.001 | −0.05 | 0.63 | −0.02 | 0.89 | −0.04 | 0.82 | −0.35 | 0.07 |
| Trabecular Density | 0.00 | 0.96 | 0.23 | <0.001 | 0.00 | 0.99 | −0.13 | 0.56 | −0.06 | 0.82 | 0.12 | 0.65 |
A and B: Relationships of pQCT-Z scores over one year with clinical parameters in CF.
| Males | Age | BMI-Z | FEV1%-predicted | Visit | ||||
|---|---|---|---|---|---|---|---|---|
| Section Modulus | −0.14 | 0.001 | 0.58 | 0.002 | 0.02 | 0.004 | 0.13 | 0.56 |
| Cortical Density | −0.07 | 0.16 | 0.11 | 0.59 | −0.01 | 0.09 | −0.27 | 0.28 |
| Cortical Area | −0.08 | 0.11 | 0.85 | <0.001 | 0.02 | 0.02 | 0.26 | 0.29 |
| Cortical Thickness | 0.09 | 0.07 | 1.03 | <0.001 | 0.01 | 0.45 | 0.35 | 0.15 |
| Periosteal Circumference | −0.15 | <0.001 | 0.38 | 0.02 | 0.02 | 0.002 | 0.10 | 0.60 |
| Endosteal Circumference | −0.12 | 0.96 | −0.06 | 0.98 | −0.30 | 0.05 | 0.01 | 0.04 |
| Trabecular Density | −0.10 | 0.09 | 0.59 | 0.02 | 0.01 | 0.25 | 0.05 | 0.86 |
^ The relationship between periosteal circumference and FEV1%-predicted (p = 0.099) was tempered with adjustment for endosteal circumference-Z with which periosteal circumference is robustly associated (β = 0.32, P < 0.001).
^ The positive relationships between periosteal circumference and BMI-Z (p < 0.001) and FEV1%-predicted (p = 0.03) but not age (p = 0.16) persisted with adjustment for endosteal circumference-Z with which periosteal circumference is robustly associated (β = 0.59, P < 0.001).